治疗遗传性血管性水肿新药艾替班特概述

艾替班特和缓激肽结构类似,与其竞争性地结合缓激肽B2受体,具有良好的药动学特性,对急性发作期遗传性血管性水肿（HAE）的患者疗效佳.同时在发病的第一时间内,患者可以安全地自我治疗.目前的文献报道提示,艾替班特治疗获得性血管性水肿（AAE）的效果与治疗HAE一样安全、有效,或许将来艾替班特也可用于AAE的治疗.

Overview of Icatibant,a New Drug against Hereditary Angioedema

Objective：To get knowledge of the latest development of icatibant,a drug against hereditary angioedema （HAE）.Methods：Many literatures on icatibant were selected from home and abroad.Results ＆ Conclusion：Icatibant is structurally similar to bradykinin and acts as a potent,selective and competitive antagonist of bradykinin type 2 receptor,it also has good pharmacokinetic profile,therefore,it is a good drug against acute episodes of HAE.At the same time,patients can cure HAE by self-administrating icatibant during an acute attack.From the epidemic factor and treatment instances,Icatibant is a safe and effective drug against acquired angioedema（AAE）.Therefore,it will be approved for the treatment of AAE in the future.